Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • Theravance Biopharma's Other Accumulated Expenses rose 1033.06% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1033.06%. This contributed to the annual value of $2.2 million for FY2024, which is 7840.45% up from last year.
  • As of Q3 2025, Theravance Biopharma's Other Accumulated Expenses stood at $1.3 million, which was up 1033.06% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Other Accumulated Expenses registered a high of $2.3 million during Q2 2022, and its lowest value of $142000.0 during Q3 2022.
  • For the 5-year period, Theravance Biopharma's Other Accumulated Expenses averaged around $1.4 million, with its median value being $1.4 million (2023).
  • In the last 5 years, Theravance Biopharma's Other Accumulated Expenses plummeted by 9224.04% in 2022 and then soared by 96338.03% in 2023.
  • Theravance Biopharma's Other Accumulated Expenses (Quarter) stood at $1.3 million in 2021, then decreased by 12.42% to $1.1 million in 2022, then grew by 8.67% to $1.2 million in 2023, then soared by 78.4% to $2.2 million in 2024, then crashed by 39.7% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.9 million for Q2 2025, and $2.1 million during Q1 2025.